(Q34926825)

English

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

Frederik Persson

1

object named as

Frederik Persson

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

4

object named as

Peter Rossing

0 references

author name string

Julia B Lewis

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Edmund J Lewis

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Norman K Hollenberg

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Hans-Henrik Parving

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

24 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Clinical Journal of the American Society of Nephrology

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1025-1031

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Lowering blood pressure reduces renal events in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Glomerular permselectivity in early stages of overt diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

8 July 2018

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Progression of nephropathy in type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Optimal dose of losartan for renoprotection in diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Glomerular hypertension as one cause of albuminuria in type II diabetic patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

26 October 2018

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

9 December 2018

Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087767

9 December 2018

[Serum creatinine determination without protein precipitation]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350110

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glomerular hemodynamics in experimental diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350110

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350110

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350110

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2215/CJN.07590810

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34926825&oldid=1606618834"